Cardax

Cardax EBITDA Margin

The EBITDA Margin of Cardax (CDXI) as of Oct 19, 2026 is -561.80 %. In the previous year, EBITDA Margin was -567.86 % — a change of -1.07% (higher).

EBITDA Margin

-561.80 %

YoY

-1.07%

Last updated:

EBITDA Margin of Cardax is 2020 -561.80 % . EBITDA Margin of Cardax was 2019 -567.86 % . It decreases by -1.07% higher compared to the previous year.

The Cardax EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2016
-5,102.27 USD
Jan 1, 2017
-323.27 USD
Jan 1, 2018
-264.21 USD
Jan 1, 2019
-567.86 USD
Jan 1, 2020
-561.80 USD
The Cardax EBITDA Margin history
YEAREBITDA MarginYoY
-561.80 %-1.07%
-567.86 %+114.93%
-264.21 %-18.27%
-323.27 %-93.66%
-5,102.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

EBITDA Margin of Cardax is -561.80 % in 2020.

EBITDA Margin of Cardax changed from -567.86 % to -561.80 %, representing a -1.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Cardax since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Cardax with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cardax

All Key Metrics — Cardax